PRO-155 is developed by Laboratorios Sophia S.A de C.V..

What development phase is PRO-155 in?

PRO-155 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

PRO-155

Laboratorios Sophia S.A de C.V. · FDA-approved active Small molecule Quality 6/100

At a glance

Generic name	PRO-155
Also known as	zebesten, bromfenac
Sponsor	Laboratorios Sophia S.A de C.V.
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo. (PHASE4)
Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers. (PHASE1)
Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PRO-155 CI brief — competitive landscape report
PRO-155 updates RSS · CI watch RSS
Laboratorios Sophia S.A de C.V. portfolio CI